等待开盘 02-07 09:30:00 美东时间
+2.940
+0.89%
Alnylam outlines its 2030 strategy, targeting TTR leadership, pipeline expansion, and strong revenue growth backed by rising product sales.
01-13 02:33
New platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipelineFDA has accepted Alnylam's enzymatic ligation manufacturing platform into its
2025-12-17 21:03
Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with wild-type or
2025-12-16 21:11
A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.
2025-12-16 20:04
As a result of the reconstitution, the following six companies will be removed from the Index: Biogen Inc. (NASDAQ:BIIB), CDW Corporation (NASDAQ:CDW), GlobalFoundries Inc. (NASDAQ:GFS), Lululemon Athletica Inc.
2025-12-15 16:10
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th
2025-10-31 01:40
BridgeBio Pharma(BBIO.US)正凭借一款心脏病药物与辉瑞(PFE.US)、Alnylam Pharmaceuticals(ALNY.US)展开竞争。该公司称其药物疗效更优且成本更低,但同时指控竞争对手在这个价值数十亿美元的市场中采用“有争议的策略”进行竞争。 争议焦点源于辉瑞本月在一场医学会议上播放的一段视频——视频中称其药物Vyndamax是治疗某类致命性心力衰竭的“首款且唯一获批疗法”,却刻意隐瞒了两项关键事实:BridgeBio的竞品药物已于2024年11月上市,而Alnylam的同类药物自今年3月起也已投入使用。BridgeBio首席执行官尼尔·库马尔(Neil K...
2025-09-12 08:27
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 来源:聪明投资者 今年以来,创新药成为公募基金收益来源的关键“胜负手”...
2025-07-22 15:03
3月20日,纳指生物科技ETF(513290)盘中涨超1%,冲击三连涨,刷新近15个月以来新高!成交额超5700万元,环比放量! 当地时间周三(3月1...
2025-03-20 13:58
Analysts' ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) over the last quart...
2025-03-12 02:00